HK Stock Market Move | BRAINAURORA-B (06681) rose over 9% on its first day of listing. The company focuses on the field of digital therapy for cognitive disorders.

On the day after its listing, BRAINAURORA-B (06681) rose by more than 9%, exceeding the IPO price of HK$3.22 by more than 13%. As of the time of writing, it had risen by 9.31% to HK$3.64, with a trading volume of HK$6.6431 million. It is reported that BRAINAURORA is the first company in China to combine brain science with artificial intelligence technology to develop medical-grade digital therapeutic products targeting cognitive disorders. The company's core product, a brain functional information management platform software system, has been commercialized for eight indications of four major types of cognitive disorders. The product pipeline covers assessments and interventions for cognitive disorders induced by vascular diseases, neurodegenerative diseases, mental disorders, and developmental defects in children. In addition to the system, BRAINAURORA currently has three other products that have been approved by regulators in China: Basic Cognitive Ability Test Software (BCAT), Cognitive Ability Assistive Screening Assessment Software (SAS), and Reading Disability Assistive Screening Assessment Software (DSS). Another product has received regulatory approval in the European Union (Cognitive Dysfunction Treatment Software), and six candidate products are in different stages of preclinical and clinical development or registration processes.